U.S. Markets closed

BioRestorative Therapies to Present at the 22nd Annual American Society of Gene and Cell Therapy as to Data on its Platform Technology for the Treatment of Metabolic Disorders

Cell Based Therapy for the Treatment of Type 2 Diabetes, Obesity, Hyperlipidemia and Hypertension

MELVILLE, N.Y., April 29, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that Francisco Silva, Vice President of Research and Development, will present at the 2019 American Society of Gene and Cell Therapy (ASGCT) to be held April 29 – May 2, 2019 in Washington D.C.

Mr. Silva will provide an update on BioRestorative’s ThermoStem® program targeted for treating metabolic disorders. This conference is the sector’s premiere forum bringing together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.

The Company’s study entitled, “Development of an Encapsulated Stem Cell Bioengineered Brown Adipose Transplant to Improve Metabolic Disorders” demonstrates the progress the Company has made in characterizing multiple brown adipose derived stem cell (BADSC) populations isolated from mediastinal and cervical anatomical locations and successfully generated metabolically active 3D brown adipose tissue (BAT). Data will also be presented on the evaluation on in vitro use of an FDA approved immune-protecting encapsulation medical device as a delivery system for bioengineered BAT transplantation.  

Transplantation of brown fat in obese mice models has demonstrated multiple beneficial metabolic outcomes, including regulating glucose homeostasis, insulin sensitivity and even reversing obesity. These findings provide a rationale for the therapeutic expansion of BAT for the treatment of metabolic disorders in humans.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.  Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells.  In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.  We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

• Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Email: ir@biorestorative.com